Company intelligence / Profile preview

Hutom

Seoul, Seoul, South Koreahutom.io ↗

Ownership: Private
Development stage: Commercial

Overview

Hutom has developed the RUS platform, an AI-powered surgical navigation system that reconstructs CT images into 3D anatomical models to assist surgeons with preoperative planning, intraoperative guidance, and postoperative analysis. The technology includes patented features such as automatic segmentation of organs/vessels and predictive modeling of abdominal distention. The company is actively collaborating with Johnson & Johnson MedTech Korea to promote this solution domestically. Clinical results focus on improved workflow efficiency for surgeons and enhanced patient outcomes through advanced visualization.

Therapeutic areas: Other
Modalities: DeviceSoftware platform (AI-based surgical navigation and analysis)
Industry: Digital Health Medical Devices

Partnerships

Johnson & Johnson MedTech Korea (co-promotion agreement for the RUS platform)

Beyond the preview

Go deeper on Hutom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hutom.

Explore the full profile